What is the significance and recommended management for a liver stiffness measurement of 15.5 kPa and a CAP (controlled attenuation parameter) median of 286 dB/m?

Liver Stiffness 15.5 kPa with CAP 286 dB/m: Cirrhosis with Significant Steatosis

This patient has cirrhosis and requires immediate initiation of hepatocellular carcinoma surveillance, variceal screening, and management of underlying liver disease. The liver stiffness measurement of 15.5 kPa exceeds the 12.5 kPa threshold for cirrhosis, and the CAP of 286 dB/m indicates significant hepatic steatosis that may influence disease progression and outcomes 1.

Interpretation of Liver Stiffness (15.5 kPa)

The LSM of 15.5 kPa definitively indicates cirrhosis. According to AGA guidelines, a cutoff of 12.5 kPa is recommended to detect cirrhosis in patients with chronic liver disease, with pooled sensitivity of 0.86 and specificity of 0.91 1. Your patient's value of 15.5 kPa is well above this threshold, placing them firmly in the cirrhotic range.

• This measurement should not be used in isolation—the AGA explicitly states that downstream decisions for invasive tests should not be based solely on the 12.5 kPa cutoff 1.
• Context matters: If the patient has active hepatic inflammation (AST or GGT >2x ULN) or recent alcohol use, the LSM may be falsely elevated and should be repeated after at least 1 week of abstinence 1.
• For variceal screening: The patient does not yet meet the 19.5 kPa threshold that would allow you to rule out high-risk esophageal varices, so upper endoscopy is still indicated 1.

Interpretation of CAP (286 dB/m)

The CAP of 286 dB/m indicates significant hepatic steatosis (≥S2). The EASL guidelines suggest that values above 275 dB/m can be used to diagnose steatosis 1. More specifically, research shows that CAP cutoffs of 302 dB/m for ≥S1, 331 dB/m for ≥S2, and 337 dB/m for S3 are appropriate 2, 3.

• Your patient's value of 286 dB/m falls between S1 and S2, indicating moderate steatosis that is clinically significant 2.
• Prognostic significance: CAP ≥220 dB/m is independently associated with increased risk of hepatic decompensation and severe bacterial infections in patients with compensated advanced chronic liver disease 4. Your patient's CAP of 286 dB/m places them at higher risk for these complications.
• Impact on LSM interpretation: Higher CAP values can cause LSM to overestimate fibrosis severity, particularly in NAFLD 5. However, at 15.5 kPa, your patient is well above the cirrhosis threshold regardless of this potential confounding effect.

Clinical Management Algorithm

Immediate Actions Required:

1. Hepatocellular carcinoma surveillance: Initiate ultrasound screening every 6 months with or without AFP, as this patient has cirrhosis 1.

2. Variceal screening: Perform upper endoscopy to screen for esophageal varices, as the LSM of 15.5 kPa does not exclude high-risk varices (threshold for exclusion is 19.5 kPa) 1.

3. Identify and treat underlying etiology:

   • Screen for viral hepatitis (HBV, HCV) 1
   • Assess for alcohol use disorder and counsel on complete abstinence 1
   • Evaluate for metabolic syndrome components (obesity, diabetes, dyslipidemia) given the significant steatosis 1
   • Consider NASH as a primary or contributing diagnosis given the elevated CAP 2

4. Address steatosis: The CAP of 286 dB/m indicates significant fat accumulation that independently increases risk of decompensation 4. Implement aggressive lifestyle modifications including weight loss (7-10% target), dietary changes, and exercise 1.

Monitoring Strategy:

• Repeat elastography: Consider repeating LSM and CAP after addressing inflammation, alcohol use, or achieving metabolic improvements to refine risk stratification 1, 4.
• If viral hepatitis is treated: Post-SVR patients with pre-treatment cirrhosis should continue HCC and portal hypertension surveillance regardless of post-treatment LSM values 1.
• Serial CAP monitoring: A decline of ≥46 dB/m or ≥15% from baseline indicates clinically relevant improvement in steatosis 6.

Critical Pitfalls to Avoid

Do not dismiss this as "borderline" cirrhosis—15.5 kPa is definitively elevated and mandates full cirrhosis management 1.

Do not attribute the entire LSM elevation to steatosis alone—while CAP can affect LSM interpretation, multivariable analysis shows that fibrosis stage is the dominant factor affecting LSM, not steatosis 2.

Do not delay variceal screening—the common misconception that LSM >12.5 kPa alone can guide endoscopy decisions is incorrect; the threshold for ruling out high-risk varices is 19.5 kPa 1.

Do not ignore the prognostic significance of elevated CAP—CAP ≥220 dB/m independently predicts clinical decompensation beyond what LSM alone provides 4.